The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis

Laura D. Carbone, Michael C. Nevitt, Kathryn Wildy, Karen D. Barrow, Fran Harris, David Felson, Charles Peterfy, Marjolein Visser, Tamara B. Harris, Benjamin W.E. Wang, Stephen B. Kritchevsky

Research output: Contribution to journalArticle

175 Scopus citations

Abstract

Objective. To examine the cross-sectional association between use of medications that have a bone antiresorptive effect (estrogen, raloxifene, and alendronate) and both the structural features of knee osteoarthritis (OA), assessed by magnetic resonance imaging (MRI) and radiography, and the symptoms of knee OA in elderly women. Methods. Women in the Health, Aging and Body Composition Study underwent MRI and radiography of the knee if they reported symptoms of knee OA, and women without significant knee symptoms were selected as controls. MR images of the knee were assessed for multiple features of OA using the Whole-Organ MRI scoring method, and radiographs were read for Kellgren and Lawrence grade and individual features of OA. Concurrent medication use and knee symptoms were assessed by interview, and knee pain severity was evaluated using the Western Ontario and McMaster Universities Osteoartkritis Index (WOMAC). Results. There were 818 postmenopausal women from whom we obtained MR images of the knee and data on medication use. Among these women, 214 (26.2%) were receiving antiresorptive drugs. We found no significant association between overall use of antiresorptive drugs and the presence of knee pain and radiographic changes of OA of the knee. Use of alendronate, but not estrogera, was associated with less severity of knee pain as assessed by WOMAC scores. Both alendronate use and estrogen use were associated with significantly less subchondral bone attrition and bone marrow edema-like abnormalities in the knee as assessed by MRI, as compared with women who had not received these medications. Conclusion. Elderly women being treated with alendronate and estrogen had a significantly decreased prevalence of knee OA-related subchondral bone lesions compared with those reporting no use of these medications. Alendronate use was also associated with a reduction in knee pain according to the WOMAC scores.

Original languageEnglish (US)
Pages (from-to)3516-3525
Number of pages10
JournalArthritis and Rheumatism
Volume50
Issue number11
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis'. Together they form a unique fingerprint.

  • Cite this

    Carbone, L. D., Nevitt, M. C., Wildy, K., Barrow, K. D., Harris, F., Felson, D., Peterfy, C., Visser, M., Harris, T. B., Wang, B. W. E., & Kritchevsky, S. B. (2004). The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis and Rheumatism, 50(11), 3516-3525. https://doi.org/10.1002/art.20627